DiscoverWavesDecks

Texas-based Actuate Therapeutics has raised $22M to expand GSK-3β c...

Texas-based Actuate Therapeutics has raised $22M to expand GSK-3β cancer trial.

Published in

Words

0

Reading

0 min

Listen

Play

2019-05-22 09:01

The Actuate Phase 1/2 study is aimed at evaluating the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor.
#cancer #therapy #pharma
https://blog.genexi.ru/news/Actuate-Secures-%2422M-to-back-Phase-I-II-Clinical-Trial-en Без названия (1).jpg

2019-05-22 09:01

This post was published via steemit. Ecency is not the originator or editor of this content and displays it for discovery purposes only.

$ 0.000

0